Open Label Single-Arm Clinical Trial with Earvaru Beeja Kalka in the Management of Benign Prostatic Hyperplasia

被引:0
|
作者
Tripathy, Rabinarayan [1 ]
Athulya, A. [1 ]
Otta, Susmita P. [2 ]
机构
[1] Amrita Univ, Sch Ayurveda, Dept Shalya Tantra, Amritapuri Campus, Amritapuri, India
[2] CCRAS, Cent Ayurveda Res Inst Hepatobiliary Disorder, Bhubaneswar, India
关键词
vatashtila; Ervaru beeja kalka; Benign prostatic hypertrophy; mutraghata;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Benign prostatic hypertrophy (BPH) is a common condition in the aging men along with lower urinary tract symptoms (LUTS). The prevalence of BPH is proportional to age. It affects 70% of men above 70 years. It is the increase in the number of stromal and glandular epithelial cells in the periurethral transitional zone of the prostate. It can be correlated to vatashtila one among the mutraghata. BPH can be managed by a conservative and surgical treatment which includes anti-androgen therapy, alpha-blockers, aromatase inhibitors, prostatectomy, laser therapy, microwave treatment. As the patients are fairly old these complications are liable to occur in early postoperative days. Even conservative therapy has disadvantages like administering anti-androgen therapy causes impotence, aromatase inhibitors which are widely used have to lead to certain side effects like lassitude, depression, gynecomastia. According to surveys, the socioeconomic burden of BPH is tremendous, costing over $3 billion every year. In this situation, Ayurveda may be able to provide a treatment that is herbal and free from any adverse effects. This research work was carried out with the ultimate aim of finding the best cost-effective treatment of BPH in comparison with available Allopathic treatment. An extensive literature review reveals that Ervaru beeja kalka along with saindhava lavana and dhanyamla is an excellent remedy for mutraghata. Ervaru beeja kalka is an excellent mutrala, balya and dosha prashamana. Also, studies reveal that chemical constituents in cucumber seed can act on the signaling pathway of the proliferation of cancer cells i n the prostate. Because of all these reasons, the present study of Earvaru beeja kalka on BPH was done.
引用
收藏
页码:86 / 90
页数:5
相关论文
共 50 条
  • [41] Evaluation of efficacy and safety of lascufloxacin for nursing and healthcare associated pneumonia: single-arm, open-label clinical trial: A study protocol
    Hosogaya, Naoki
    Takazono, Takahiro
    Ota, Kenji
    Kiya, Rieko
    Shirai, Yumi
    Kawasaki, Rina
    Yano, Hiroshi
    Morimoto, Shinpei
    Nakao, Rumiko
    Kanamaru, Yumiko
    Yoshino, Yukari
    Ishikawa, Yasuyuki
    Fukushima, Chizu
    Yamamoto, Hiroshi
    Izumikawa, Koichi
    Yanagihara, Katsunori
    Mukae, Hiroshi
    MEDICINE, 2023, 102 (08)
  • [42] Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial
    Ali A. Mokdad
    Hao Zhu
    Muhammad S. Beg
    Yull Arriaga
    Jonathan E. Dowell
    Amit G. Singal
    Adam C. Yopp
    Targeted Oncology, 2019, 14 : 541 - 550
  • [43] Comment on: Sirolimus for patients with connective tissue disease-related refractory thrombocytopenia: a single-arm, open-label clinical trial
    Banday, Aaqib Zaffar
    Jindal, Ankur Kumar
    RHEUMATOLOGY, 2021, 60 (06) : E211 - E212
  • [44] EFFICACY AND SAFETY OF SILODOSIN AND DUTASTERIDE COMBINATION THERAPY IN ACUTE URINARY RETENTION DUE TO BENIGN PROSTATIC HYPERPLASIA: A SINGLE-ARM PROSPECTIVE STUDY
    Imai, Atsushi
    Yamamoto, Hayato
    Hatakeyama, Shingo
    Yoneyama, Takahiro
    Hashimoto, Yasuhiro
    Koie, Takuya
    Kamimura, Noritaka
    Yoshikawa, Kazuaki
    Kyan, Atsushi
    Kawaguchi, Toshiaki
    Kusumi, Yasuo
    Yagihashi, Yuji
    Ohyama, Chikara
    JOURNAL OF UROLOGY, 2015, 193 (04): : E331 - E332
  • [45] Optimization of individualized faricimab dosing for patients with diabetic macular edema: Protocol for the SWAN open-label, single-arm clinical trial
    Hirano, Takao
    Murata, Toshinori
    Nakao, Shintaro
    Shimura, Masahiko
    Nozaki, Miho
    Suzuma, Kiyoshi
    Nagaoka, Taiji
    Sugimoto, Masahiko
    Takamura, Yoshihiro
    Murakami, Tomoaki
    Iwasaki, Keisuke
    Tsujimura, Jun
    Yoshida, Shigeo
    PLOS ONE, 2024, 19 (10):
  • [46] Effect of Personalized Prebiotic and Probiotic Supplements on the Symptoms of Irritable Bowel Syndrome: An Open-Label, Single-Arm, Multicenter Clinical Trial
    Matsuura, Nozomi
    Kanayama, Masaya
    Watanabe, Yuta
    Yamada, Hirokazu
    Lili, Loukia
    Torii, Akira
    NUTRIENTS, 2024, 16 (19)
  • [47] SIROLIMUS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS RELATED THROMBOCYTOPENIA (SLE-TP): A SINGLE-ARM, OPEN-LABEL CLINICAL TRIAL
    Wu, Chanyuan
    Wang, Qian
    Li Mengtao
    Zeng, Xiaofeng
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 787 - 787
  • [48] Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial
    Mokdad, Ali A.
    Zhu, Hao
    Beg, Muhammad S.
    Arriaga, Yull
    Dowell, Jonathan E.
    Singal, Amit G.
    Yopp, Adam C.
    TARGETED ONCOLOGY, 2019, 14 (05) : 541 - 550
  • [49] Efficacy and Safety of Silodosin and Dutasteride Combination Therapy in Acute Urinary Retention due to Benign Prostatic Hyperplasia: A Single-Arm Prospective Study
    Hagiwara, Kazuhisa
    Koie, Takuya
    Iwamura, Hiromichi
    Imai, Atsushi
    Hatakeyama, Shingo
    Yoneyama, Takahiro
    Hashimoto, Yasuhiro
    Ohyama, Chikara
    BIOMED RESEARCH INTERNATIONAL, 2016, 2016
  • [50] Clinical Efficacy and Safety of Naftopidil Treatment for Patients with Benign Prostatic Hyperplasia and Hypertension: A Prospective, Open-Label Study
    Chung, Mun Su
    Yoon, Byung Il
    Lee, Seung Hwan
    YONSEI MEDICAL JOURNAL, 2017, 58 (04) : 800 - 806